jf97: Your threatening language to the mods is way out of line. Our mods have equitably supervised the best CYDY message board in existence -- a thankless task that consumes considerable amounts of their time.

As to your question: based on my avid perusal of board content over the last 4+ years, as well as my own circumstances, I would surmise that those board members having an interest, or even a preference, for a BO would often be older investors who have taken far more aggressive position on a small, underfunded biotech than prudent due a formed conviction that Leronlimab is a once in a generation drug that ought to provide exceedingly uncommon investment returns as well as exceedingly uncommon health benefits to mankind.

If LL is as exceptional as ohm and the rest of us true believers have bet that it is, a BO (even at a reasonable price) would likely be antithetical to maximizing potential investment returns. However, as I attempted to communicate in a recent post, a BO from a prosperous, well established BP (like Merck) would hugely mitigate the risk of clinical trial operation snafus and FDA intransigence regarding LL approval, as well as totally eliminate funding concerns. So, in terms of making LL available to sick people as quickly as possible, I submit that many board members, not unreasonably, see a BO as preferable to other strategies. Accordingly, I see board members willing to countenance the prospect of an appropriately priced BO offer as a group of investors willing to accept reduced potential investment returns as a means of eliminating their unhealthy, excessive financial exposure to CYDY, while at the same time significantly enhancing the likelihood of LL's FDA approval. That viewpoint, I submit, is open to reasonable debate, but it is not inherently evil or unconscionable under the existing circumstances confronting CYDY and LL.